Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF (2001) Proc Natl Acad Sci U S A 98: 13288-93 Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA, Antiretroviral Therapy Cohort Collaboration (2014) Clin Infect Dis 59: 287-97 Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Haas DW (2006) Clin Infect Dis 42: 1197-9 Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Spritzler J, Mildvan D, Russo A, Asthana D, Livnat D, Schock B, Kagan J, Landay A, Haas DW, Adult AIDS Clinical Trials Group (2003) Clin Infect Dis 37: 551-8 Oxidant stress is increased during treatment of human immunodeficiency virus infection. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW (2003) Clin Infect Dis 37: 1711-7 An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR (2011) Clin Infect Dis 53: 952-60 Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration (2014) Int J Epidemiol 43: 691-702 Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW (2006) AIDS 20: 1503-13 European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA (2011) AIDS 25: 37-47 Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR (2013) AIDS 27: 1321-9 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC) (2013) AIDS 27: 803-13 Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA (2005) AIDS 19: 1341-9 Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia. Koethe JR, Limbada MI, Giganti MJ, Nyirenda CK, Mulenga L, Wester CW, Chi BH, Stringer JS (2010) AIDS 24: 2117-21 Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY, Protocol 054/069 Study Teams (2000) AIDS 14: 1973-8 Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M, Protocol AI424-009 Study Group (2003) AIDS 17: 1339-49 Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A, AIDS Clinical Trials Group (2006) J Infect Dis 194: 1098-107 Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (2011) J Infect Dis 204: 893-901 Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. Wellons MF, Ottinger JS, Weinhold KJ, Gryszowka V, Sanders LL, Edwards LJ, Gooding ME, Thomasch JR, Bartlett JA (2001) J Infect Dis 183: 1522-5 Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW, DS Clinical Trials Group (2013) J Infect Dis 207: 420-5 African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T, AIDS Clinical Trials Group Study 384 Team, New Work Concept Sheet 273 Team (2010) J Infect Dis 201: 1703-7 CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR (2005) J Infect Dis 192: 950-7 Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR (2007) J Infect Dis 195: 425-31 Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP (2009) J Infect Dis 199: 991-8 Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR (2010) Epidemiology 21: 698-705 Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T (2009) J Clin Epidemiol 62: 729-37 The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Canter JA, Haas DW, Kallianpur AR, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Murdock DG, Hulgan T (2008) Pharmacogenomics J 8: 71-7 Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team (2007) Pediatrics 120: e1190-202 The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of Kaposi's sarcoma (KS) in a cohort of HIV-infected men. Luu HN, Amirian ES, Scheurer ME (2013) Br J Cancer 108: 1173-7 Race, kidney disease progression, and mortality risk in HIV-infected persons. Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA (2010) Clin J Am Soc Nephrol 5: 2269-75 Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA (2003) J Acquir Immune Defic Syndr 34: 475-81 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM (2017) J Acquir Immune Defic Syndr 75: 568-576 Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR (2011) J Acquir Immune Defic Syndr 57: 305-10 Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia. Zulu I, Schuman P, Musonda R, Chomba E, Mwinga K, Sinkala M, Chisembele M, Mwaba P, Kasonde D, Vermund SH (2004) J Acquir Immune Defic Syndr 36: 831-4 The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy. Hart AB, Samuels DC, Hulgan T (2013) AIDS Rev 15: 213-20 Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in Zambia. Koethe JR, Blevins M, Nyirenda C, Kabagambe EK, Shepherd BE, Wester CW, Zulu I, Chiasera JM, Mulenga LB, Mwango A, Heimburger DC (2011) J Int AIDS Soc 14: 19 Increased Black-White disparities in mortality after the introduction of lifesaving innovations: a possible consequence of US federal laws. Levine RS, Rust GS, Pisu M, Agboto V, Baltrus PA, Briggs NC, Zoorob R, Juarez P, Hull PC, Goldzweig I, Hennekens CH (2010) Am J Public Health 100: 2176-84 Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T (2011) PLoS One 6: e18462 Serum phosphate predicts early mortality in adults starting antiretroviral therapy in Lusaka, Zambia: a prospective cohort study. Heimburger DC, Koethe JR, Nyirenda C, Bosire C, Chiasera JM, Blevins M, Munoz AJ, Shepherd BE, Potter D, Zulu I, Chisembele-Taylor A, Chi BH, Stringer JS, Kabagambe EK (2010) PLoS One 5: e10687 A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics. Koethe JR, Westfall AO, Luhanga DK, Clark GM, Goldman JD, Mulenga PL, Cantrell RA, Chi BH, Zulu I, Saag MS, Stringer JS (2010) PLoS One 5: e9680 Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW (2014) Pharmacogenet Genomics 24: 195-203
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.